235 related articles for article (PubMed ID: 28389391)
1. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.
Maurer M; Schütz A; Weller K; Schoepke N; Peveling-Oberhag A; Staubach P; Müller S; Jakob T; Metz M
J Allergy Clin Immunol; 2017 Sep; 140(3):870-873.e5. PubMed ID: 28389391
[No Abstract] [Full Text] [Related]
2. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
[No Abstract] [Full Text] [Related]
3. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial.
Metz M; Schütz A; Weller K; Gorczyza M; Zimmer S; Staubach P; Merk HF; Maurer M
J Allergy Clin Immunol; 2017 Sep; 140(3):864-867.e5. PubMed ID: 28389393
[No Abstract] [Full Text] [Related]
4. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
5. What are the effects of omalizumab in refractory chronic spontaneous urticaria?
López M; Navajas-Galimany L
Medwave; 2015 Dec; 15 Suppl 3():e6346. PubMed ID: 26731420
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
7. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
Di Leo E; Calogiuri G; Macchia L; Nettis E
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
[No Abstract] [Full Text] [Related]
8. Chronic inducible urticaria: A systematic review of treatment options.
Dressler C; Werner RN; Eisert L; Zuberbier T; Nast A; Maurer M
J Allergy Clin Immunol; 2018 May; 141(5):1726-1734. PubMed ID: 29438771
[TBL] [Abstract][Full Text] [Related]
9. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU.
Ertaş R; Hawro T; Altrichter S; Özyurt K; Erol K; Ketenci Ertaş Ş; Maurer M
Allergy; 2020 Feb; 75(2):468-470. PubMed ID: 31469912
[No Abstract] [Full Text] [Related]
10. Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.
Casale TB; Win PH; Bernstein JA; Rosén K; Holden M; Iqbal A; Trzaskoma BL; Yang M; Antonova EN; Murphy T; Scarupa MD; Sofen H; Kaplan A
J Am Acad Dermatol; 2018 Apr; 78(4):793-795. PubMed ID: 29037993
[No Abstract] [Full Text] [Related]
11. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.
Zazzali JL; Kaplan A; Maurer M; Raimundo K; Trzaskoma B; Solari PG; Antonova E; Mendelson M; Rosén KE
Ann Allergy Asthma Immunol; 2016 Oct; 117(4):370-377.e1. PubMed ID: 27424128
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.
Gastaminza G; Azofra J; Nunez-Cordoba JM; Baeza ML; Echechipía S; Gaig P; García BE; Labrador-Horrillo M; Sala-Cunill A; Brescó MS; Beristain A; Quiñones D; Donado CD; Zubeldia JM; Ferrer M
J Allergy Clin Immunol Pract; 2019; 7(5):1599-1609.e1. PubMed ID: 30654196
[TBL] [Abstract][Full Text] [Related]
13. Allergic skin diseases.
Lang DM; Fineman SM; Khan DA; Tilles SA
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):580-582. PubMed ID: 29705380
[No Abstract] [Full Text] [Related]
14. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.
Harris JM; Cabanski CR; Scheerens H; Samineni D; Bradley MS; Cochran C; Staubach P; Metz M; Sussman G; Maurer M
J Allergy Clin Immunol; 2016 Dec; 138(6):1730-1732. PubMed ID: 27567329
[No Abstract] [Full Text] [Related]
16. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China.
Chen YD; Maurer M; Yu M; Tu P; Zhao ZT
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):217-219. PubMed ID: 32371240
[No Abstract] [Full Text] [Related]
17. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
[No Abstract] [Full Text] [Related]
19. "Chronic Urticaria": Recommendations From an Allergist and Immunologist.
Awosika O; Qureshi A; Ehrlich A; Fonacier L
Dermatitis; 2018; 29(5):292-293. PubMed ID: 30179970
[No Abstract] [Full Text] [Related]
20. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C.
Leiva-Salinas M; Francés L; Marin-Cabanas I; Arribas Granados MP; Silvestre JF
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1027-8. PubMed ID: 24629127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
